Successful treatment with reduced-intensity stem cell transplantation in a case of relapsed refractory central nervous system lymphoma

被引：14

作者：

Aoyama, Y ^{[1
]}

Yamamura, R ^{[1
]}

Shima, E ^{[1
]}

Nakamae, H ^{[1
]}

Makita, K ^{[1
]}

Kho, G ^{[1
]}

Ohta, K ^{[1
]}

Yamane, T ^{[1
]}

Takubo, T ^{[1
]}

Hino, M ^{[1
]}

机构：

[1] Osaka City Univ, Dept Clin Hematol & Clin Diagnost, Grad Sch Med, Abeno Ku, Osaka 5458586, Japan

来源：

ANNALS OF HEMATOLOGY | 2003年 / 82卷 / 06期

关键词：

allogeneic stem cell transplantation; central nervous system lymphoma; reduced-intensity stem cell transplantation; graft-versus-lymphoma effect;

D O I：

10.1007/s00277-003-0651-z

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

A 33-year-old male with refractory relapsed central nervous system lymphoma underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) from an HLA-identical sibling after reduced-intensity conditioning chemotherapy. The preparative regimen for allo-HSCT consisted of fludarabine and busulfan. Cyclosporine (CsA) and short-term methotrexate were used as prophylaxis for acute graft-versus-host disease (GVHD). Although CsA was quickly reduced to induce a graft-versus-lymphoma (GVL) effect, no symptoms of GVHD and GVL effect were evident. Donor lymphocyte infusion (DLI) was performed on day +40 following transplantation. The patient developed acute GVHD (grade III) after DLI, and lymphoma regression was observed after the occurrence of GVHD. Four months after transplantation, complete remission was achieved with extensive chronic GVHD, and the patient continues to be disease free at 15 months after transplantation.

引用

页码：371 / 373

页数：3

共 10 条

[1] High-dose chemotherapy with autologous stem cell transplantation is an effective treatment of primary refractory Hodgkin's disease.: Retrospective study of the Polish Lymphoma Research Group [J].

Czyz, J ;

Hellmann, A ;

Dziadziuszko, R ;

Hansz, J ;

Gozdzik, J ;

Holowiecki, J ;

Stella-Holowiecka, B ;

Kachel, L ;

Knopinska-Posluszny, W ;

Nagler, A ;

Meder, J ;

Walewski, J ;

Lampka, E ;

Sulek, K ;

Sawicki, W ;

Lange, A ;

Forgacz, K ;

Suchnicki, K ;

Pacuszko, T ;

Skotnicki, A ;

Mensah, P ;

Jurczak, W ;

Kuliczkowski, K ;

Wróbel, T ;

Mazur, G ;

Dmoszynska, A ;

Wach, M ;

Robak, T ;

Warzocha, K .

BONE MARROW TRANSPLANTATION, 2002, 30 (01) :29-34

[2] Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy:: Results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 trial [J].

Fermé, C ;

Mounier, N ;

Diviné, M ;

Brice, P ;

Stamatoullas, A ;

Reman, O ;

Voillat, L ;

Jaubert, J ;

Lederlin, P ;

Colin, P ;

Berger, F ;

Salles, G .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (02) :467-475

[3] Allogeneic stem cell transplantation for the non-Hodgkin's lymphomas and Hodgkin's disease [J].

Hale, GA ;

Phillips, GL .

CANCER TREATMENT REVIEWS, 2000, 26 (06) :411-427

[4] Reduced-intensity allogeneic transplantation for lymphoma [J].

Kogel, KE ;

McSweeney, PA .

CURRENT OPINION IN ONCOLOGY, 2002, 14 (05) :475-483

[5] Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR) [J].

Lazarus, HM ;

Loberiza, FR ;

Zhang, MJ ;

Armitage, JO ;

Ballen, KK ;

Bashey, A ;

Bolwell, BJ ;

Burns, LJ ;

Freytes, CO ;

Galeg, RP ;

Gibson, J ;

Herzig, RH ;

LeMaistre, CF ;

Marks, D ;

Mason, J ;

Miller, AM ;

Milone, GA ;

Pavlovsky, S ;

Reece, DE ;

Rizzo, JD ;

van Besien, K ;

Vose, JM ;

Horowitz, MM .

BONE MARROW TRANSPLANTATION, 2001, 27 (04) :387-396

[6]

RATANATHARATHORN V, 1994, BLOOD, V84, P1050

[7] Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases [J].

Slavin, S ;

Nagler, A ;

Naparstek, E ;

Kapelushnik, Y ;

Aker, M ;

Cividalli, G ;

Varadi, G ;

Kirschbaum, M ;

Ackerstein, A ;

Samuel, S ;

Amar, A ;

Brautbar, C ;

Ben-Tal, O ;

Eldor, A ;

Or, R .

BLOOD, 1998, 91 (03) :756-763

[8] Management of lymphoma recurrence after allogeneic transplantation: The relevance of graft-versus-lymphoma effect [J].

vanBesien, KW ;

deLima, M ;

Giralt, SA ;

Moore, DF ;

Khouri, IF ;

Rondon, G ;

Mehra, R ;

Andersson, BS ;

Dyer, C ;

Cleary, K ;

Przepiorka, D ;

Gajewski, JL ;

Champlin, RE .

BONE MARROW TRANSPLANTATION, 1997, 19 (10) :977-982

[9] Allogeneic bone marrow transplantation for poor-prognosis lymphoma: Response, toxicity, and survival depend on disease histology [J].

vanBesien, KW ;

Mehra, RC ;

Giralt, SA ;

Kantarjian, HM ;

Pugh, WC ;

Khouri, IF ;

Moon, Y ;

Williams, P ;

Andersson, BS ;

Przepiorka, D ;

McCarthy, PL ;

Gajewski, JL ;

Deisseroth, AB ;

Cabanillas, FF ;

Champlin, R .

AMERICAN JOURNAL OF MEDICINE, 1996, 100 (03) :299-307

[10] Graft-versus-lymphoma effect after allogeneic peripheral blood stem cell transplantation for primary central nervous system lymphoma [J].

Varadi, G ;

Or, R ;

Kapelushnik, J ;

Naparstek, E ;

Nagler, A ;

Brautbar, C ;

Amar, A ;

Kirschbaum, M ;

Samuel, S ;

Slavin, S ;

Siegal, T .

LEUKEMIA & LYMPHOMA, 1999, 34 (1-2) :185-190

← 1 →